Bayer’s Pharmaceuticals Research & Development division is working on potential future therapies for patients with cardiomyopathies of a genetic background for whom a therapy is currently not available.
We would like to use the stem cells to generate heart muscle cells and to investigate the differences of those cells in comparison to a healthy state to develop new therapeutic opportunities.
What we're looking for
We are seeking stem cells from patients with dilated cardiomyopathies (e.g. laminopathy or others). The genetic defect in those patients causing the disease should be known. Further, we would need certain clinical parameters of those patients. We would NOT use the cells themselves for clinical research & development.
Solutions of interest include:
Induced pluripotent stem cells (iPSCs) from patients with dilated cardiomyopathies
Our must-have requirements are:
The genetic defect in those patients causing the disease must be known
The allowance by the donors to do research & development with the results of investigating those cells to develop human therapies.
The allowance to use the induced pluripotent stem cells (iPSCs) to expand, reproduce, do gene sequencing, do expression analysis and further utilize
You must be able to show us the detailed wording of the patient informed consent, if requested.
Our nice-to-have's are:
Proven differentiation into cardiomyocytes
Examined phenotype of cells
Heart tissue from those patients instead of cells
What's out of scope:
Embryonic stems cells
Cells derived from animals
Acceptable technology readiness levels (TRL):
Levels 2-4
What we can offer you
Eligible partnership models:
Sponsored research
Licensing
Supply/purchase
Benefits:
Sponsored Research
We are interested in follow-on research collaborations with relevant teams, including sponsored research or involvement of collaborators on a consultancy basis.
Who we are
Bayer is a German multinational pharmaceutical and life sciences company with a more than 150-year history and core competencies in the areas of health care and agriculture.
We develop hair loss treatments, which few based on stem cells (iPSC). While not sure if we align fully with your 'must-have requirements', we see potential collaboration. If interested will continue to the proposal stage
Gorden Redlich, Head of Strategic Outsourcing & Externalization, Bayer Pharma
April 18, 2024
Is this response helpful?
0
0
Q.
What is the timeline you are looking for - we have a patient registry, some sequencing of HCM heart tissue, and an iPSC biobank but have yet to consent patients for iPSC donation.
Gorden Redlich, Head of Strategic Outsourcing & Externalization, Bayer Pharma
May 6, 2024
Is this response helpful?
0
0
Q.
I am Professor Ofer Binah, Technion, Israel. I have iPSCs and iPSC-CMs from DCM laminopathy and DMD patients (papers published). Please inform the next step for initiating a collaboration with Bayer Pharma.